Together, they launched the first Brain Health Collaboratory. This new model aims to accelerate the discovery, validation and real-world delivery of non-drug neurotherapies. They aim to merge clinical care, AI-powered research and continuous data into a single learning healthcare ecosystem.
With this initiative, Cognito says they could transform how degenerative diseases, cognitive decline and brain injuries are studied and treated.
The initiative centers around Cognito’s investigational Spectris neuroprotective device designed for home use. The company developed its non-invasive Spectris device to deliver proprietary gamma frequency light and sound stimulation. This evokes EEG-confirmed gamma frequency brain oscillations to treat central nervous system (CNS) diseases. It restores brain electrical activity disrupted in Alzheimer’s disease (AD). Recent study findings demonstrated the potential efficacy of the investigational device.
Cognito said the Brain Health Collaboratory builds upon RNI’s ecosystem and integrates Spectris into RNI’s clinical workflows. This should enable real-time therapy delivery, data collection and adaptive learning. It also supports full-stack R&D, real-world data analytics and commercialization planning.
This marks the first step in a planned network of collaboratories, Cognito said. It aims to establish new ones with leading academic medical centers to form a new infrastructure for brain health.
Commentary from Cognito and RNI officials
Christian Howell, CEO of Cognito Therapeutics, said:
“This is a rare inflection point where science, technology, and healthcare systems converge to transform how we treat brain disease. Spectris has the potential to change millions of lives, but realizing that promise requires bold, global collaboration and entirely new models of evidence generation. The Brain Health Collaboratory embodies that vision.”
Dr. Ali Rezai, executive chair of the Rockefeller Neuroscience Institute, said:
“We are proud to launch this pioneering partnership with Cognito Therapeutics. This collaboratory brings together two institutions committed to rapidly advancing the treatment of neurological disease. RNI’s legacy in translational research makes us uniquely suited to help realize the full potential of Spectris from early discovery through system-wide implementation.”
